- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
回复 tonychant 的帖子
http://www.medscape.com/viewarticle/743978
Renal Effect of Tenofovir Is Milder When It's Used Only for HBVBy C. Vidya Shenkar MD
NEW YORK (Reuters Health) Jun 03 - Monotherapy for hepatitis B virus infection with tenofovir or other polymerase inhibitors affects kidneys only mildly, new research shows.
That's in dramatic contrast to what's been seen when tenofovir is used in antiretroviral combinations for HIV.
"According to our observations all HBV-polymerase inhibitors seem reasonably safe concerning renal function in HBV monotherapy," said lead researcher Dr. Stefan Mauss from the Center for HIV and Hepatogastroenterology, Duesseldorf, Germany, in an email to Reuters Health.
In a study reported online May 19th in the Journal of Hepatology, Dr. Mauss and colleagues used mathematical models to predict yearly median individual changes in renal function with various polymerase inhibitors given as monotherapy for isolated hepatitis B infection. For comparison, they also applied the models to patients with isolated HIV receiving polymerase inhibitor containing combinations.
Glomerular filtration rates (GFR) were derived from serum creatinine measurements. Projected annual changes in GFR were estimated with linear mixed effect models. Baseline renal function was normal in both groups.
The hepatitis B group included 36 patients on lamivudine, 32 on adefovir, 32 on entecavir and 37 on tenofovir monotherapy. Sixty untreated hepatitis B positive patients served as controls. The HIV group included 120 patients receiving tenofovir, 52 receiving zidovudine and not tenofovir, and 109 who were treatment naive.
The projected annual decline in GFR in the HBV group was less than 1 ml/min overall, 0.92ml/min with lamivudine or tenofovir, 1.02ml/min with adefovir, and 1.00 ml/min with entecavir. The predicted annual GFR decline was 2.05 ml/min in untreated controls.
In the HIV group, the predicted renal function decline was significantly greater with tenofovir based combinations (2.64 ml/min) than with zidovudine (1.00 ml/min). The predicted GFR decline in untreated patients was similar to the decline with zidovudine.
"Due to the study size this statement accounts only for general drug effects and not rare events," Dr. Mauss said
C.维迪亚申卡尔博士
纽约(路透社健康)6月03 - 诺福韦或其他聚合酶抑制剂的B型肝炎病毒感染的单药治疗只影响肾脏轻度,新的研究表明。
这是什么泰诺福韦在艾滋病毒的抗逆转录病毒药物组合使用时,在巨大反差。
首席研究员斯特凡·莫斯博士说:“根据我们的观察,所有的乙肝病毒聚合酶抑制剂似乎合理的安全程度的肾功能在HBV单一,从艾滋病毒和胃肠肝胆,杜塞尔多夫,德国的中心,在路透社的电子邮件。
在一项研究报告在线5月19日,在肝病,博士和同事利用数学模型预测每年的中位数在个别单一孤立的B型肝炎感染的各种聚合酶抑制剂的肾功能变化莫斯杂志。作比较,他们也适用于隔离艾滋病毒的患者接受含有聚合酶抑制剂组合模型。
肾小球滤过率(GFR),推导出从血肌酐测量。在GFR预计每年的变化,估计与线性混合效应模型。两组基线肾功能正常。
B型肝炎组包括36例拉米夫定,阿德福韦酯32,32恩替卡韦和替诺福韦单药治疗37。第六未经治疗的乙肝阳性的患者作为对照组。艾滋病毒组包括120例患者接受替诺福韦,52接受齐多夫定,而不是替诺福韦,109治疗殿。
在HBV组预计在GFR每年下降不到1毫升/分钟的整体,0.92ml/min与拉米夫定或替诺福韦与阿德福韦1.02ml/min,1.00毫升/分钟用恩替卡韦。预测每年GFR下降为2.05毫升/分钟在未经处理的控制。
在艾滋病毒组,预测肾功能下降显着大于泰诺福韦(2.64毫升/分钟)的组合与齐多夫定(1.00毫升/分钟)。未经治疗的患者中预测的GFR下降是类似与齐多夫定的下降。
“莫斯博士说,”由于研究规模占本声明仅适用于一般的药物效果并不罕见事件
|
-
总评分: 现金 + 3
查看全部评分
|